RecoveryMedium Risk
LL-37
Also known as: cathelicidin, CAP18
- Half-life:
- ~30 minutes
Administration Routes
subcutaneous injectiontopicalintravenous
PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.
Mechanism of Action
Human cathelicidin antimicrobial peptide; disrupts bacterial membranes and modulates innate immune response via TLR signaling
The only known human cathelicidin, with broad-spectrum antimicrobial and immunomodulatory activity. Promotes wound healing and combats bacterial biofilms.
Primary Research Areas
- antimicrobial
- immune modulation
- wound healing
- anti-biofilm
Risk Profile
Medium Risk
Moderate risk profile in research contexts. Consult a healthcare professional before use.
Regulatory Status
Research OnlyInvestigational
Human cathelicidin antimicrobial peptide. Phase 1/2 trials for wound healing. No FDA approval, no NDA. Early investigational stage only. Not commercially available in US.
Regulatory status reflects publicly available information and may change. This is not legal or medical advice.